Orforglipron oral overcomes semaglutide in glycemic control and weight loss
SESTO FIORENTINO (ITALPRESS) – Eli Lilly and Company today announced the detailed results of ACHIEVE-3, the first Phase 3 head-to-head study that assessed the safety and effectiveness of orforglipron, a small agonist oral molecule of the GLP-1 receptor without restrictions […]
Orforglipron oral overcomes semaglutide in glycemic control and weight loss Read More »










